Gain Therapeutics Inc has a consensus price target of $8 based on the ratings of 6 analysts. The high is $10 issued by Maxim Group on September 12, 2023. The low is $5 issued by B. Riley Securities on August 19, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on July 11, 2024, July 2, 2024, and May 31, 2024, respectively. With an average price target of $8.33 between HC Wainwright & Co., there's an implied 716.99% upside for Gain Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/11/2024 | Buy Now | 684.31% | HC Wainwright & Co. | Raghuram Selvaraju | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
07/02/2024 | Buy Now | 684.31% | HC Wainwright & Co. | Raghuram Selvaraju | $9 → $8 | Maintains | Buy | Get Alert |
05/31/2024 | Buy Now | 782.35% | HC Wainwright & Co. | Raghuram Selvaraju | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
05/28/2024 | Buy Now | 782.35% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
05/15/2024 | Buy Now | 782.35% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
04/25/2024 | Buy Now | 782.35% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
04/23/2024 | Buy Now | 782.35% | Oppenheimer | Hartaj Singh | → $9 | Maintains | Outperform | Get Alert |
04/01/2024 | Buy Now | 782.35% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
03/27/2024 | Buy Now | 488.24% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
12/04/2023 | Buy Now | 782.35% | HC Wainwright & Co. | Raghuram Selvaraju | $10 → $9 | Maintains | Buy | Get Alert |
09/18/2023 | Buy Now | 880.39% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
09/12/2023 | Buy Now | 880.39% | Maxim Group | Jason McCarthy | → $10 | Initiates | → Buy | Get Alert |
08/31/2023 | Buy Now | 880.39% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
08/14/2023 | Buy Now | 488.24% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
08/14/2023 | Buy Now | 880.39% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
06/12/2023 | Buy Now | 880.39% | Oppenheimer | Hartaj Singh | → $10 | Reiterates | Outperform → Outperform | Get Alert |
05/15/2023 | Buy Now | 880.39% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
05/15/2023 | Buy Now | 488.24% | Chardan Capital | Keay Nakae | $5.75 → $6 | Maintains | Buy | Get Alert |
05/01/2023 | Buy Now | 880.39% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | → Buy | Get Alert |
03/27/2023 | Buy Now | 463.73% | Chardan Capital | Keay Nakae | $4 → $5.75 | Maintains | Buy | Get Alert |
12/09/2022 | Buy Now | 292.16% | Chardan Capital | Keay Nakae | → $4 | Initiates | → Buy | Get Alert |
11/25/2022 | Buy Now | 880.39% | Oppenheimer | Hartaj Singh | $30 → $10 | Maintains | Outperform | Get Alert |
11/14/2022 | Buy Now | 880.39% | HC Wainwright & Co. | Raghuram Selvaraju | $12 → $10 | Maintains | Buy | Get Alert |
11/14/2022 | Buy Now | 880.39% | BTIG | Thomas Shrader | $30 → $10 | Maintains | Buy | Get Alert |
08/19/2022 | Buy Now | 390.2% | B. Riley Securities | Mayank Mamtani | $11 → $5 | Downgrade | Buy → Neutral | Get Alert |
03/29/2022 | Buy Now | 1468.63% | B. Riley Securities | Mayank Mamtani | $21 → $16 | Maintains | Buy | Get Alert |
03/29/2022 | Buy Now | 1076.47% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Initiates | → Buy | Get Alert |
11/03/2021 | Buy Now | 1958.82% | B. Riley Securities | Mayank Mamtani | — | Initiates | → Buy | Get Alert |
The latest price target for Gain Therapeutics (NASDAQ:GANX) was reported by HC Wainwright & Co. on July 11, 2024. The analyst firm set a price target for $8.00 expecting GANX to rise to within 12 months (a possible 684.31% upside). 15 analyst firms have reported ratings in the last year.
The latest analyst rating for Gain Therapeutics (NASDAQ:GANX) was provided by HC Wainwright & Co., and Gain Therapeutics reiterated their buy rating.
There is no last upgrade for Gain Therapeutics
The last downgrade for Gain Therapeutics Inc happened on August 19, 2022 when B. Riley Securities changed their price target from $11 to $5 for Gain Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on July 11, 2024 so you should expect the next rating to be made available sometime around July 11, 2025.
While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a reiterated with a price target of $8.00 to $8.00. The current price Gain Therapeutics (GANX) is trading at is $1.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.